CN112220916A - 生物酶片剂的制备工艺及其产品 - Google Patents
生物酶片剂的制备工艺及其产品 Download PDFInfo
- Publication number
- CN112220916A CN112220916A CN202011153503.4A CN202011153503A CN112220916A CN 112220916 A CN112220916 A CN 112220916A CN 202011153503 A CN202011153503 A CN 202011153503A CN 112220916 A CN112220916 A CN 112220916A
- Authority
- CN
- China
- Prior art keywords
- enzyme
- percent
- preparing
- biological
- bio
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000004190 Enzymes Human genes 0.000 title claims abstract description 48
- 108090000790 Enzymes Proteins 0.000 title claims abstract description 48
- 238000002360 preparation method Methods 0.000 title claims abstract description 26
- 239000002245 particle Substances 0.000 claims abstract description 26
- 239000000463 material Substances 0.000 claims abstract description 19
- 238000002156 mixing Methods 0.000 claims abstract description 13
- 238000003825 pressing Methods 0.000 claims abstract description 9
- 102000038379 digestive enzymes Human genes 0.000 claims abstract description 7
- 108091007734 digestive enzymes Proteins 0.000 claims abstract description 7
- 229940088598 enzyme Drugs 0.000 claims description 57
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 33
- 229920002472 Starch Polymers 0.000 claims description 19
- 239000008187 granular material Substances 0.000 claims description 19
- 235000019698 starch Nutrition 0.000 claims description 19
- 239000008107 starch Substances 0.000 claims description 19
- 239000004382 Amylase Substances 0.000 claims description 12
- 102000013142 Amylases Human genes 0.000 claims description 12
- 108010065511 Amylases Proteins 0.000 claims description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 12
- 235000019418 amylase Nutrition 0.000 claims description 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 108091005804 Peptidases Proteins 0.000 claims description 10
- 239000004365 Protease Substances 0.000 claims description 10
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 10
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 9
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 9
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 9
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 9
- 102000004882 Lipase Human genes 0.000 claims description 8
- 108090001060 Lipase Proteins 0.000 claims description 8
- 239000004367 Lipase Substances 0.000 claims description 8
- 239000000853 adhesive Substances 0.000 claims description 8
- 230000001070 adhesive effect Effects 0.000 claims description 8
- 235000019421 lipase Nutrition 0.000 claims description 8
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 7
- 229930006000 Sucrose Natural products 0.000 claims description 7
- 229960004793 sucrose Drugs 0.000 claims description 7
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 6
- 108010059892 Cellulase Proteins 0.000 claims description 6
- 239000011575 calcium Substances 0.000 claims description 6
- 229910052791 calcium Inorganic materials 0.000 claims description 6
- 235000001465 calcium Nutrition 0.000 claims description 6
- 229940106157 cellulase Drugs 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 235000019359 magnesium stearate Nutrition 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 239000000377 silicon dioxide Substances 0.000 claims description 6
- 235000012239 silicon dioxide Nutrition 0.000 claims description 6
- 239000002002 slurry Substances 0.000 claims description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 229920000881 Modified starch Polymers 0.000 claims description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 230000006835 compression Effects 0.000 claims 1
- 238000007906 compression Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 32
- 238000000034 method Methods 0.000 abstract description 16
- 238000005550 wet granulation Methods 0.000 abstract description 5
- 238000003860 storage Methods 0.000 abstract description 3
- 230000004071 biological effect Effects 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 36
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 18
- 239000012085 test solution Substances 0.000 description 18
- 239000000523 sample Substances 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 239000000047 product Substances 0.000 description 10
- 239000012488 sample solution Substances 0.000 description 10
- 238000005303 weighing Methods 0.000 description 10
- 238000000227 grinding Methods 0.000 description 8
- 238000004448 titration Methods 0.000 description 8
- 238000002835 absorbance Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 239000005018 casein Substances 0.000 description 5
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 5
- 235000021240 caseins Nutrition 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 5
- 235000019345 sodium thiosulphate Nutrition 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 238000009835 boiling Methods 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000004570 mortar (masonry) Substances 0.000 description 4
- 239000004006 olive oil Substances 0.000 description 4
- 235000008390 olive oil Nutrition 0.000 description 4
- 229920001592 potato starch Polymers 0.000 description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- XTLNYNMNUCLWEZ-UHFFFAOYSA-N ethanol;propan-2-one Chemical compound CCO.CC(C)=O XTLNYNMNUCLWEZ-UHFFFAOYSA-N 0.000 description 3
- 239000013022 formulation composition Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 239000007974 sodium acetate buffer Substances 0.000 description 3
- BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical compound [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000012490 blank solution Substances 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000019626 lipase activity Nutrition 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000010008 shearing Methods 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 238000009423 ventilation Methods 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- RSJOBNMOMQFPKQ-UHFFFAOYSA-L copper;2,3-dihydroxybutanedioate Chemical compound [Cu+2].[O-]C(=O)C(O)C(O)C([O-])=O RSJOBNMOMQFPKQ-UHFFFAOYSA-L 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940079919 digestives enzyme preparation Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000010200 folin Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920001903 high density polyethylene Polymers 0.000 description 1
- 239000004700 high-density polyethylene Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000004537 pulping Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/01—Carboxylic ester hydrolases (3.1.1)
- C12Y301/01003—Triacylglycerol lipase (3.1.1.3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01001—Alpha-amylase (3.2.1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01004—Cellulase (3.2.1.4), i.e. endo-1,4-beta-glucanase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了生物酶片剂的制备工艺及其产品,制备工艺是具体是先用辅料制备成空白颗粒,然后将一种或多种生物酶与空白颗粒混合均匀后,临压前加入辅料,压片制得消化酶片剂;该方法直接将生物酶进行压片,避免了湿法制粒工艺过程中酶活性的损失,因此制得的生物酶片剂生物活性高,并且在贮存过程中酶活性降低少,质量稳定。
Description
技术领域
本发明涉及制药领域,具体涉及消化酶片剂的制备工艺,还涉及制得的消化酶制剂。
背景技术
消化酶片是含高效淀粉酶、脂肪酶和蛋白酶的复合酶制剂,对食物中淀粉、蛋白质、纤维素和脂肪有良好酶促分解作用,从而帮助机体纠正消化道功能紊乱,促进营养成分的吸收,治疗单纯性消化不良和改善体质。受生产工艺过程的影响,各厂家及不同批次的酶制剂产品差异性较大,在生产、贮存过程中酶活性易下降,导致临床疗效不稳定。进口药中仅有德国的康彼身、美国产的意康绿消化酶、加拿大产的健美生、日本进口的美尼等成分与消化酶片相近,但价格昂贵,不能满足普通消费者的需要;因此开发出经济有效、质量稳定、酶活性强、贮存期长的酶制剂很有必要。
发明内容
有鉴于此,本发明的目的在于提供一种生物酶片剂的制备工艺,该工艺通过将生物酶、辅料空白颗粒及滑料混合后进行压片,避免了湿法制粒过程中生物酶活性的损失,工艺简单易操作,经济实用。
为实现上述发明目的本发明提供如下技术方案:
1、一种生物酶片剂的制备工艺,具体是先用辅料制备成空白颗粒,然后将一种或多种生物酶与空白颗粒混合均匀后,临压前加入辅料(简称临压辅料),压片制得消化酶片剂。
本发明优选的,所述空白颗粒的含水量小于6.0%,粒径小于2.0mm。
本发明中,所述空白颗粒的制备过程:先将辅料加入高效湿法制粒机中混合均匀,然后加入粘合剂溶液,制成均匀细沙状湿颗粒,将湿颗粒干燥至水分小于6.0%,再将干颗粒整粒收集粒径小于2.0mm的颗粒,得到空白颗粒;所述粘合剂溶液为5wt%~7wt%的淀粉浆。
本发明中,所述片剂中各组分的重量百分比分别为:生物酶粉10%~20%,空白颗粒60%~90%,临压前加入辅料0.4%~25%。
本发明中,所述生物酶为淀粉酶、纤维素酶、蛋白酶以及脂肪酶中的一种或多种。
本发明中,所述空白颗粒的制备辅料为蔗糖,乳糖,淀粉,预胶化淀粉,糊精,磷酸氢钙,微晶纤维素中的一种或多种。
本发明中,所述临压前加入辅料为微晶纤维素,二氧化硅,滑石粉以及硬脂酸镁中的一种或多种。
本发明中,所述空白颗粒各组分中重量分数如下:磷酸氢钙12%~45.2%,淀粉15.9~37.8%,蔗糖10%;所述生物酶粉各组分如下:生物淀粉酶10%,酒曲蛋白酶6.5%,脂肪酶2.2%;所述临压前加入辅料各组分如下:硬脂酸镁0.5%,二氧化硅0.5%,微晶纤维素9.2%~20.5%;更有选的,空白颗粒的各组分重量比为磷酸氢钙27.1%,淀粉27.7%,蔗糖10%。
2、所述的制备工艺制得的生物酶片剂。
本发明的有益效果在于:本发明公开了生物酶制剂的制备工艺,该工艺直接将生物酶进行压片,避免了湿法制粒过程中生物酶活性的损失,因此制得的生物酶片剂生物活性高,并且在贮存过程中酶活性降低少,质量稳定。
具体实施方式
下面结合具体实施例对本发明作进一步说明,以使本领域的技术人员可以更好的理解本发明并能予以实施,但所举实施例不作为对本发明的限定。
为了降低湿法制粒过程中酶活性的损失,选择先将辅料制成空白颗粒,然后将生物酶混粉、空白颗粒以及临压辅料混合均匀后进行压片;严格控制压片机的主压力,降低机械外力对生物酶活性的影响。
实施例1
本实施例的生物酶制剂的处方组成及比例见表1。
表1、样品1的处方
*:生物淀粉酶为淀粉酶和纤维素酶的复合酶,下同。
本实施例的生物酶制剂的制备步骤如下:
①将6.08g淀粉用纯化水冲稀释成5%的淀粉浆121.6g,搅拌均匀,作为粘合剂备用。
②将411.92g磷酸氢钙、410.4g淀粉、152g蔗糖以加入湿法制粒机中,搅拌混合均匀;然后加入步骤①配制的粘合剂,搅拌剪切形成细沙状湿颗粒;
③将步骤②制得的湿颗粒移入沸腾干燥制粒器中,设定进风温度70~75℃,物料温度保持在60~65℃左右,通风干燥至水分小于6.0%;整粒机安装2.0mm孔径的不锈钢筛网整粒,将干颗粒分散成均匀颗粒。
④将步骤③制得的干颗粒移入混合器中,然后加入7.6g硬脂酸镁、240.16g微晶纤维素、7.6g二氧化硅、152g生物淀粉酶、98.8g酒曲蛋白酶、33.44g脂肪酶混合30分钟后压片;选用浅凹型的冲模,片重约为152mg。
本实施例中处方中的组分可调,具体如表2所示:
表2、样品2和样品3的处方
因此,本实施例中可调组分的重量分数范围如下:磷酸氢钙12.0%~45.2%,干加淀粉15.2%~37.5%,制浆淀粉0.3%~0.7%,微晶纤维素9.2%~20.5%。
实施例2~实施例3
实施例2~实施例3除了生物酶制剂的处方组成及比例与实施例1不同,其余部分相同(见表3)。
表3、样品4和样品5的处方
实施例4
实施例4采用将生物酶粉进行湿法制粒之后压片的工艺进行对比研究,处方组成及比例见表4。
表4、样品6的处方
本实施例的生物酶制剂的制备步骤如下:
①将7.87g淀粉用纯化水冲稀释成5%的淀粉浆157.4g,搅拌均匀,作为粘合剂备用。
②将411.92g磷酸氢钙、408.61g淀粉、152g蔗糖、152g生物淀粉酶、98.8g酒曲蛋白酶、33.44g脂肪酶加入湿法制粒机中,搅拌混合均匀。然后加入步骤①配制的粘合剂,搅拌剪切形成细沙状湿颗粒;
③将步骤②制得的湿颗粒移入沸腾干燥制粒器中,设定进风温度70~75℃,物料温度保持在60~65℃左右,通风干燥至水分小于6.0%。整粒机安装2.0mm孔径的不锈钢筛网整粒,将干颗粒分散成均匀颗粒。
测定实施例1~4制得酶制剂的效果数据
1)淀粉酶活力的测定
淀粉酶:取本品20片,精密称定,研细,精密称取约0.075g,置研钵中,加少量水研磨,移至250ml量瓶中,加水至刻度,摇匀、即得。
测定法:精密量取1%马铃薯淀粉溶液(取经105℃干燥2小时的马铃薯淀粉1.0g,加水10ml摇匀后边搅拌边缓缓加入2mol/L氢氧化钠溶液5ml使成糊状,置沸水浴中加热5分钟,加水25ml,放冷,用2mol/L盐酸溶液和0.1mol/L盐酸溶液调节pH值为7.0±0.1,再加pH值为5.0的醋酸—醋酸钠缓冲液10ml与水至100ml)10ml至碘量瓶中,置于37±0.5℃恒温水浴中保温10~15分钟,精密加入供试品溶液1ml,摇匀,立即置于37±0.5℃水浴中准确反应10分钟。加碱性酒石酸铜试液4ml,充分振摇,加盖,于沸水浴中准确加热15分钟,取出,于流水中冷却后,加浓碘化钾试液2ml,加25%硫酸溶液2ml与淀粉试液2滴,摇匀,用硫代硫酸钠滴定液(0.05mol/L)滴定至无色(A)。
另取10ml水代替马铃薯淀粉溶液,依法操作,记录消耗的硫代硫酸钠滴定液的体积(B)。
在上述条件下,每分钟分解马铃薯淀粉相当于1mg葡萄糖的酶量,为1个活力单位。
每片含淀粉酶活力单位=(B-A)×1.8×f×1/10×n×平均片重/取样量;
B为空白消耗硫代硫酸钠的体积(ml);
A为供试品消耗硫代硫酸钠的体积(ml);
f为硫代硫酸钠滴定液浓度的换算系数;
n为供试样品溶液的稀释倍数。
2)蛋白酶活力的测定
蛋白酶供试品溶液的制备:取本品20片,精密称定,研细,精密称取约0.45g,置研钵中,加少量冷的0.002mol/L盐酸溶液研磨,移至100ml量瓶中,加相同溶液至刻度,摇匀,即得。
测定法:精密量取酪蛋白溶液(称取105℃干燥至恒重的酪蛋白1.2g置于200ml的量瓶中,加水150ml和乳酸试液12ml,置60~70℃水浴中,不时振摇,溶解15分钟,放冷,用1mol/L氢氧化钠溶液调节pH值至3.0后,加水至刻度,摇匀)5ml至试管中,置于37±0.5℃恒温水浴中放置10~15分钟后,精密加入供试品溶液1ml,摇匀,立即置37±0.5℃恒温水浴中准确反应10分钟,加0.11mol/L三氯醋酸溶液5ml,充分振摇混合,再置37±0.5℃恒温水浴中放置30分钟,滤过,滤液备用。
精密量取0.55mol/L碳酸钠试液5ml置比色管中,精密加上述滤液2ml与稀释的福林试液(1→3)1ml,充分振摇混匀,置37±0.5℃恒温水浴中放置30分钟,以水作为对照,在660nm波长处测定吸收度(AT)。
另精密量取酪蛋白溶液5ml,加0.11mol/L三氯醋酸溶液5ml混匀,精密加入供试品溶液1ml,同法测定吸收度(AB)。
在上述条件下,每分钟分解酪蛋白相当于1μg酪氨酸的酶量,为1个活力单位。
每片含蛋白酶活力单位=(AT-AB)×F×11/2×1/10×n×平均片重/取样量。
AT:供试品溶液的吸收度值
AB:空白溶液的吸收度值
F:标准曲线中吸收度差值为1.000时的酪氨酸的量
n:供试品溶液的稀释倍数
3)脂肪酶活力的测定
脂肪酶供试品溶液的制备:取本品20片,精密称定,研细,精密称取约0.45g,置乳钵中,加少量冷却的枸橼酸钠溶液(pH6.0)研磨,移至100ml量瓶中,并用相同溶液稀释至刻度,摇匀,即得。
测定法:取磷酸盐缓冲液(pH6.0)4ml与橄榄油乳化液5ml置烧杯中,混匀,在37±0.5℃恒温水浴中放置10~15分钟后,精密加供试品溶液1ml,充分混合,在37±0.5℃恒温水浴中准确反应20分钟。加乙醇-丙酮混合液(1∶1)10ml,充分振摇。精密加0.05mol/L氢氧化钠溶液10ml与加乙醇-丙酮混合液(1∶1)10ml,用氮气边吹液面,边用搅拌器搅拌的条件下,用盐酸滴定液(0.05mol/L)滴定至反应液的pH值恒定在10.0。以pH计指示终点,记录消耗盐酸滴定液的量(V1)。
另取磷酸盐缓冲液4ml(pH6.0)与橄榄油乳化液5ml,置100ml烧杯中,加乙醇-丙酮混合液(1∶1)10ml,混匀,再精密加供试品溶液1ml,在37±0.5℃恒温水浴中准确反应20分钟后,自“精密加0.05mol/l氢氧化钠溶液10ml…”起,同法操作,记录消耗盐酸滴定液的量(V0)。
在上述条件下,每分钟分解脂肪(橄榄油)生成1μmol脂肪酸的酶量,为1个活力单位。
每片脂肪酶活力单位=50×(V0–V1)×f×1/20×n×平均片重/取样量
V1:为供试品溶液消耗盐酸滴定液(0.05mol/L)的体积(ml);
V0:为空白溶液消耗盐酸滴定液(0.05mol/L)的体积(ml);
F:为盐酸滴定液浓度的换算系数;
n:为供试品溶液稀释倍数。
4)纤维素酶活力的测定
纤维素酶供试品溶液的制备:取本品20片,精密称定,研细,精密称取约0.135g,置乳钵中,加少量水研磨,移至100ml量瓶中,加水至刻度,摇匀,即得。
测定法:取羧甲基纤微素钠溶液4ml至50ml纳氏比色管中,置37±0.5℃恒温水浴中预热10~15分钟,精密加供试品溶液1ml.摇匀,于37±0.5水浴中反应30分钟,加碱性铜试液2ml,摇匀,加塞,于沸水浴中再准确反应30分钟,取出放冷后,加砷钼酸铵试液2ml,充分振摇混匀后,再加0.5mol/L氢氧化钠试液3ml,振摇使沉淀溶解,放置20分钟,加醋酸-醋酸钠缓冲液(pH4.5)使成25ml,精密量取1ml置100ml量瓶中,用加醋酸-醋酸钠缓冲液(pH4.5)稀释至刻度,摇匀,以水作空白,在750nm波长处分别测定吸收度(AT)。另取羧甲基纤维素钠溶液4ml,加碱性铜试液2ml及供试品溶液1ml,摇匀,自“于沸水浴中准确反应30分钟”起同法操作,测定吸收度(AB)。用AT减去AB所得之差,从葡萄糖标准曲线中,求出供试品溶液相当于葡萄糖的量(C)。
在上述条件下,每分钟分解羧甲基纤维素钠相当于1μmol葡萄糖的酶量,为1个活力单位。
每片含纤维素酶活力单位=C×n×1/0.18×1/30×平均片重/称样重×1000
C:为供试品溶液相当于葡萄糖的量;
n:为供试品溶液稀释倍数。
酶活性测定:结果见表5。
表5、样品酶活性结果
结果显示样品1~样品5中各个酶活性值均符合要求,且都在较高活力值范围,表明5种制剂处方合理,且整个制剂过程酶活性的损失较小;而样品6的各个酶活性值显著低于样品1的各个酶活性值,表明湿法制粒过程会使酶活性损失。
长期实验:将样品1采用口服固体药用高密度聚乙烯瓶包装,放置在稳定性试验箱中,调节温度25℃±2℃,湿度60%±5%,分别于3、6、9、12、18、24、36取样,重点考察本品的外观色泽、酶活力、微生物限度。试验结果见表6。
表6、样品1长期试验结果
样品1在长期留样试验条件下3年,虽然随着时间的推移酶活力有逐步降低的趋势,色泽也有加深的现象;但是外观色泽、酶活力及微生物限度各项指标均符合质量标准的规定,说明样品1在考察期内酶活性降低较少,质量基本稳定。
以上所述实施例仅是为充分说明本发明而所举的较佳的实施例,本发明的保护范围不限于此。本技术领域的技术人员在本发明基础上所作的等同替代或变换,均在本发明的保护范围之内。本发明的保护范围以权利要求书为准。
Claims (10)
1.一种生物酶片剂的制备工艺,其特征在于:具体是先用辅料制备成空白颗粒,然后将一种或多种生物酶与空白颗粒混合均匀后,临压前加入辅料,压片制得消化酶片剂。
2.根据权利要求1所述生物酶片剂的制备工艺,其特征在于:所述空白颗粒的含水量小于6.0%,粒径小于2.0mm。
3.根据权利要求1所述生物酶片剂的制备工艺,其特征在于所述空白颗粒的制备过程:先将辅料加入高效湿法制粒机中混合均匀,然后加入粘合剂溶液,制成均匀细沙状湿颗粒,将湿颗粒干燥至水分小于6.0%,再将干颗粒整粒收集粒径小于2.0mm的颗粒,得到空白颗粒;所述粘合剂溶液为5wt%~7wt%的淀粉浆。
4.根据权利要求1所述生物酶片剂的制备工艺,其特征在于:所述片剂中各组分的重量百分比分别为:生物酶粉2%~20%,空白颗粒40%~90%,临压前加入辅料0.1%~40%。
5.根据权利要求4所述生物酶片剂的制备工艺,其特征在于:所述片剂中各组分的重量百分比分别为:生物酶粉10%~20%,空白颗粒60%~90%,临压前加入辅料0.4%~25%。
6.根据权利要求1任一项所述生物酶片剂的制备工艺,其特征在于:所述生物酶为淀粉酶、纤维素酶、蛋白酶以及脂肪酶中的一种或多种。
7.根据权利要求1任一项所述生物酶片剂的制备工艺,其特征在于:所述空白颗粒的制备辅料为蔗糖,乳糖,淀粉,预胶化淀粉,糊精,磷酸氢钙,微晶纤维素中的一种或多种。
8.根据权利要求1任一项所述生物酶片剂的制备工艺,其特征在于:所述临压前加入辅料为微晶纤维素,二氧化硅,滑石粉以及硬脂酸镁中的一种或多种。
9.根据权利要求1~8所述生物酶片剂的制备工艺,其特征在于:所述空白颗粒各组分中重量分数如下:磷酸氢钙12%~45.2%,淀粉15.9%~37.8%,蔗糖10%;所述生物酶粉各组分如下:生物淀粉酶10%,酒曲蛋白酶6.5%,脂肪酶2.2%;所述临压前加入辅料各组分如下:硬脂酸镁0.5%,二氧化硅0.5%,微晶纤维素9.2%~20.5%。
10.权利要求1~9任一项所述的制备工艺制得的生物酶片剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011153503.4A CN112220916A (zh) | 2020-10-26 | 2020-10-26 | 生物酶片剂的制备工艺及其产品 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011153503.4A CN112220916A (zh) | 2020-10-26 | 2020-10-26 | 生物酶片剂的制备工艺及其产品 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112220916A true CN112220916A (zh) | 2021-01-15 |
Family
ID=74110553
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011153503.4A Pending CN112220916A (zh) | 2020-10-26 | 2020-10-26 | 生物酶片剂的制备工艺及其产品 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112220916A (zh) |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57120527A (en) * | 1980-12-03 | 1982-07-27 | Bayer Ag | Manufacture of tablets containing stabilized kallikrein |
JP2006257049A (ja) * | 2005-03-18 | 2006-09-28 | Kimura Sangyo Kk | 生菌剤や消化酵素剤およびその両方を含有する錠剤の製造方法およびそれによる錠剤 |
CN1943783A (zh) * | 2006-09-27 | 2007-04-11 | 常州千红生化制药有限公司 | 复方消化酶制剂及其制备方法 |
CN101269217A (zh) * | 2007-11-19 | 2008-09-24 | 北京星昊医药股份有限公司 | 复方消化酶定位释放胶囊 |
CN102416170A (zh) * | 2011-11-07 | 2012-04-18 | 重庆申高生化制药有限公司 | 多酶片的生产工艺 |
CN102813637A (zh) * | 2012-08-31 | 2012-12-12 | 济南维尔康生化制药有限公司 | 一种胰激肽原酶肠溶片剂及其制备方法 |
CN102813636A (zh) * | 2012-08-28 | 2012-12-12 | 西南药业股份有限公司 | 那格列奈片及其制备方法 |
CN102946872A (zh) * | 2010-05-03 | 2013-02-27 | 阿普塔利斯制药有限公司 | 包含含有胰酶的消化酶混合物的微丸组合物 |
CN103055128A (zh) * | 2013-02-01 | 2013-04-24 | 山东华信制药集团股份有限公司 | 一种健胃消食片的制备工艺 |
CN103285383A (zh) * | 2013-06-03 | 2013-09-11 | 海南通用同盟药业有限公司 | 一种包含菠萝蛋白酶的药物组合物及菠萝蛋白酶肠溶片 |
CN105121618A (zh) * | 2013-04-30 | 2015-12-02 | 杜邦营养生物科学有限公司 | 制备酶片剂的方法 |
CN110882281A (zh) * | 2019-11-30 | 2020-03-17 | 江苏艾兰得营养品有限公司 | 一种益生菌肠溶片剂及其制备方法 |
-
2020
- 2020-10-26 CN CN202011153503.4A patent/CN112220916A/zh active Pending
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57120527A (en) * | 1980-12-03 | 1982-07-27 | Bayer Ag | Manufacture of tablets containing stabilized kallikrein |
JP2006257049A (ja) * | 2005-03-18 | 2006-09-28 | Kimura Sangyo Kk | 生菌剤や消化酵素剤およびその両方を含有する錠剤の製造方法およびそれによる錠剤 |
CN1943783A (zh) * | 2006-09-27 | 2007-04-11 | 常州千红生化制药有限公司 | 复方消化酶制剂及其制备方法 |
CN101269217A (zh) * | 2007-11-19 | 2008-09-24 | 北京星昊医药股份有限公司 | 复方消化酶定位释放胶囊 |
CN102946872A (zh) * | 2010-05-03 | 2013-02-27 | 阿普塔利斯制药有限公司 | 包含含有胰酶的消化酶混合物的微丸组合物 |
CN102416170A (zh) * | 2011-11-07 | 2012-04-18 | 重庆申高生化制药有限公司 | 多酶片的生产工艺 |
CN102813636A (zh) * | 2012-08-28 | 2012-12-12 | 西南药业股份有限公司 | 那格列奈片及其制备方法 |
CN102813637A (zh) * | 2012-08-31 | 2012-12-12 | 济南维尔康生化制药有限公司 | 一种胰激肽原酶肠溶片剂及其制备方法 |
CN103055128A (zh) * | 2013-02-01 | 2013-04-24 | 山东华信制药集团股份有限公司 | 一种健胃消食片的制备工艺 |
CN105121618A (zh) * | 2013-04-30 | 2015-12-02 | 杜邦营养生物科学有限公司 | 制备酶片剂的方法 |
CN103285383A (zh) * | 2013-06-03 | 2013-09-11 | 海南通用同盟药业有限公司 | 一种包含菠萝蛋白酶的药物组合物及菠萝蛋白酶肠溶片 |
CN110882281A (zh) * | 2019-11-30 | 2020-03-17 | 江苏艾兰得营养品有限公司 | 一种益生菌肠溶片剂及其制备方法 |
Non-Patent Citations (4)
Title |
---|
《药剂学》编写组: "《药剂学》", 30 September 2011 * |
胡英,等: "《药物制剂 第二版》", 28 February 2013 * |
胡贤松: "多酶片的工艺改进", 《医药工业》 * |
董纯周,等: "消化酶片的工艺质量研究", 《医药前沿》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4455764B2 (ja) | 固体フィターゼ組成物 | |
US8846361B2 (en) | Solid phytase compositions stabilized with corn steep liquor | |
SU733624A1 (ru) | Способ производства хлебного кваса | |
BG98661A (en) | Fermentation additive to fodder for animals and method for its preparation and utilization | |
DK1931215T6 (en) | Fodermiddeladditiver containing L-lysine | |
CN110959762B (zh) | 酵母水解物及其制备方法和应用 | |
CN102827910A (zh) | 一种小肽螯合铜复合物的制备方法与应用 | |
CN112220916A (zh) | 生物酶片剂的制备工艺及其产品 | |
TWI362418B (en) | Improved extraction methods and assays for feed enzymes | |
CN101658165B (zh) | 甲哌鎓泡腾片剂及其制备方法 | |
CN111978189A (zh) | 甘氨酸络合锰盐预混料的制备方法及生产系统 | |
US20060165674A1 (en) | Granular composition and process for producing the same | |
EP2244584B1 (en) | Process for preparing feed and feed additives of enhanced nutritive value from industrial by-products containing vegetable oils | |
EP3723506B1 (en) | Granulate comprising an enzyme, a carrier and a vegetable oil | |
EP4368697A1 (en) | High immune yeast cell wall, and preparation method therefor and use thereof | |
EP0513914A1 (en) | Stabilization of the enzyme urate oxidase in liquid form | |
US4010073A (en) | Free-flowing enzyme composition | |
CN102586210B (zh) | 一种固体耐高温酸性甘露聚糖酶的制作方法 | |
US4116772A (en) | Free-flowing fungal enzyme composition | |
SU893201A1 (ru) | Способ переработки хлореллы | |
CN109266719B (zh) | 麦芽淀粉水解能力评价方法 | |
CN116806960A (zh) | 一种新型淀粉酶及其在发酵食品中的应用 | |
JPS60500318A (ja) | 菌類の醗酵による酵素β↓−グルカナ−ゼの製法 | |
JPS62166831A (ja) | 改良小麦粉およびその製造法 | |
CN112831386A (zh) | 一种苦荞白酒的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210115 |
|
RJ01 | Rejection of invention patent application after publication |